Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983976 | 0.86 | ADORA3 (0.40) | PRMT6ADORA2AADORA2B | |
| SCHEMBL29674405 | 0.86 | ADORA3 (0.40) | PRMT6ADORA2AADORA2B | |
| SCHEMBL22984018 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL29674419 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL29772235 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL19509816 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL19509705 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL10459187 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL9945534 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B | |
| SCHEMBL3360473 | 0.84 | PDE4A (0.47) | P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394331-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | PRMT6 2924/4885P2RY12 659/4885ADORA2A 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.